Clinical Trial Update: A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

View source ↗

Summary

A Phase 4 prospective, multicenter, open-label observational study to evaluate real-world safety, tolerability, and treatment patterns of pegcetacoplan (Syfovre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• SYFOVRE (pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: Geographic Atrophy | Status: ACTIVE_NOT_RECRUITING